PE20190632A1 - Compuestos 8-(azetidin-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y metodos de utilizacion de los mismos - Google Patents
Compuestos 8-(azetidin-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y metodos de utilizacion de los mismosInfo
- Publication number
- PE20190632A1 PE20190632A1 PE2019000482A PE2019000482A PE20190632A1 PE 20190632 A1 PE20190632 A1 PE 20190632A1 PE 2019000482 A PE2019000482 A PE 2019000482A PE 2019000482 A PE2019000482 A PE 2019000482A PE 20190632 A1 PE20190632 A1 PE 20190632A1
- Authority
- PE
- Peru
- Prior art keywords
- azetidin
- compounds
- piridinyl
- triazolo
- pirazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A COMPUESTOS 8-(AZETIDIN-1-IL)-[1,2,4]TRIAZOLO[1,5-A]PIRIDINILO DE FORMULA (I) O (II) DONDE EL ANILLO A ES FENILO, PIRIDINILO, PIRAZOLILO O ISOQUINOLINILO; EL ANILLO B ES FENILO O HETEROARILO DE 5-6 ELEMENTOS; n ES 0, 1 O 2; R2 ES -C(O)-NH-(ALQUILO C1-C6 SUSTITUIDO OPCIONALMENTE CON HALOGENO, OH O CN), ENTRE OTROS; R3, R4 Y R5 SON CADA UNO H, CH3, CH2CH3, ENTRE OTROS; R6 ES H O ALQUILO C1-C3; R1a ES HALOGENO, ALQUILO C1-C6 SUSTITUIDO OPCIONALMENTE CON HALOGENO, CN O OH, ALCOXI C1-C6, ENTRE OTROS; R1b Y R1c JUNTOS FORMAN UN HETEROCICLOALQUILO DE 3 A 10 ELEMENTOS SUSTITUIDO OPCIONALMENTE CON ALQUILO C1-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-[3-(4-ETIL-1H-PIRAZOL-1-IL)-1-[2-([1-[2-(4-METILPIPERAZIN-1-IL)-2-OXOETIL]-1H-PIRAZOL-4-IL]AMINO)-[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-8-IL]AZETIDIN-3-IL]ACETONITRILO; 2-[3-(4,4-DIFLUORO-1-PIPERIDIL)-1-[2-[[1-[2-(4-METILPIPERAZIN-1-IL)-2-OXO-ETIL]PIRAZOL-4-IL]AMINO]-[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-8-IL]AZETIDIN-3-IL]ACETONITRILO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LAS QUINASAS DE JANUS (JAK) SIENDO UTILES EN EL TRATAMIENTO DE ASMA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016098215 | 2016-09-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190632A1 true PE20190632A1 (es) | 2019-04-26 |
Family
ID=59761965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019000482A PE20190632A1 (es) | 2016-09-06 | 2017-09-02 | Compuestos 8-(azetidin-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y metodos de utilizacion de los mismos |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20190202822A1 (es) |
| EP (2) | EP4198036A1 (es) |
| JP (1) | JP7050761B2 (es) |
| KR (1) | KR20190045302A (es) |
| CN (1) | CN109890817B (es) |
| AU (1) | AU2017324281A1 (es) |
| BR (1) | BR112019004486A2 (es) |
| CA (1) | CA3035712A1 (es) |
| CL (1) | CL2019000568A1 (es) |
| CO (1) | CO2019002171A2 (es) |
| CR (1) | CR20190118A (es) |
| IL (1) | IL265153A (es) |
| MA (1) | MA46176A (es) |
| MX (1) | MX2019002627A (es) |
| PE (1) | PE20190632A1 (es) |
| PH (1) | PH12019500478A1 (es) |
| RU (1) | RU2019109570A (es) |
| SG (1) | SG11201901954XA (es) |
| WO (1) | WO2018046409A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114008050A (zh) * | 2019-06-18 | 2022-02-01 | 豪夫迈·罗氏有限公司 | Jak激酶的吡唑并嘧啶芳基醚抑制剂及其用途 |
| GB202213164D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| WO2024148184A1 (en) * | 2023-01-04 | 2024-07-11 | Aerie Pharmaceuticals, Inc. | Compounds and processes for the preparation of jak inhibitors |
| WO2024148186A1 (en) * | 2023-01-04 | 2024-07-11 | Aerie Pharmaceuticals, Inc. | Polymorphs of a jak1/tyk2 inhibitor and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| WO1997002289A1 (en) | 1995-07-06 | 1997-01-23 | Zeneca Limited | Peptide inhibitors of fibronectine |
| US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
| JP4486817B2 (ja) | 2001-12-20 | 2010-06-23 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | １，４−ジヒドロ−１，４−ジフェニルピリジン誘導体 |
| SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
| EP2288260A4 (en) * | 2008-06-20 | 2013-10-23 | Genentech Inc | TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD |
| WO2010010184A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
| MX2011012961A (es) | 2009-06-05 | 2012-01-30 | Cephalon Inc | Preparacion y usos de derivados de 1,2,4-triazolo[1,5a]-piridina. |
| US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| RS61482B1 (sr) * | 2013-05-17 | 2021-03-31 | Incyte Corp | Derivati bipirazola kao inhibitori jak |
| EP3041841B1 (en) | 2013-09-05 | 2019-06-05 | F. Hoffmann-La Roche AG | Triazolopyridine compounds, compositions and methods of use thereof |
| EP3265464A1 (en) * | 2015-03-04 | 2018-01-10 | F. Hoffmann-La Roche AG | Triazolopyridine compounds and methods of use thereof |
-
2017
- 2017-09-02 JP JP2019512740A patent/JP7050761B2/ja active Active
- 2017-09-02 CR CR20190118A patent/CR20190118A/es unknown
- 2017-09-02 PE PE2019000482A patent/PE20190632A1/es unknown
- 2017-09-02 EP EP23150608.0A patent/EP4198036A1/en active Pending
- 2017-09-02 AU AU2017324281A patent/AU2017324281A1/en not_active Abandoned
- 2017-09-02 BR BR112019004486A patent/BR112019004486A2/pt not_active Application Discontinuation
- 2017-09-02 SG SG11201901954XA patent/SG11201901954XA/en unknown
- 2017-09-02 KR KR1020197009674A patent/KR20190045302A/ko not_active Application Discontinuation
- 2017-09-02 WO PCT/EP2017/072034 patent/WO2018046409A1/en active Application Filing
- 2017-09-02 MX MX2019002627A patent/MX2019002627A/es unknown
- 2017-09-02 CN CN201780066617.5A patent/CN109890817B/zh active Active
- 2017-09-02 EP EP17761254.6A patent/EP3510030B1/en active Active
- 2017-09-02 MA MA046176A patent/MA46176A/fr unknown
- 2017-09-02 CA CA3035712A patent/CA3035712A1/en not_active Abandoned
- 2017-09-02 RU RU2019109570A patent/RU2019109570A/ru not_active Application Discontinuation
-
2019
- 2019-03-04 IL IL265153A patent/IL265153A/en unknown
- 2019-03-05 PH PH12019500478A patent/PH12019500478A1/en unknown
- 2019-03-05 US US16/293,129 patent/US20190202822A1/en not_active Abandoned
- 2019-03-06 CL CL2019000568A patent/CL2019000568A1/es unknown
- 2019-03-08 CO CONC2019/0002171A patent/CO2019002171A2/es unknown
-
2020
- 2020-05-08 US US16/870,602 patent/US20200270248A1/en not_active Abandoned
-
2023
- 2023-04-07 US US18/297,546 patent/US20230242530A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230242530A1 (en) | 2023-08-03 |
| CR20190118A (es) | 2019-04-30 |
| MA46176A (fr) | 2019-07-17 |
| CN109890817B (zh) | 2022-06-17 |
| CO2019002171A2 (es) | 2019-05-21 |
| PH12019500478A1 (en) | 2019-12-02 |
| WO2018046409A1 (en) | 2018-03-15 |
| SG11201901954XA (en) | 2019-04-29 |
| EP3510030B1 (en) | 2023-03-22 |
| RU2019109570A (ru) | 2020-10-08 |
| CL2019000568A1 (es) | 2019-07-12 |
| US20190202822A1 (en) | 2019-07-04 |
| US20200270248A1 (en) | 2020-08-27 |
| BR112019004486A2 (pt) | 2019-05-28 |
| CN109890817A (zh) | 2019-06-14 |
| MX2019002627A (es) | 2019-10-30 |
| KR20190045302A (ko) | 2019-05-02 |
| RU2019109570A3 (es) | 2020-10-08 |
| JP7050761B2 (ja) | 2022-04-08 |
| JP2019526593A (ja) | 2019-09-19 |
| IL265153A (en) | 2019-05-30 |
| EP4198036A1 (en) | 2023-06-21 |
| AU2017324281A1 (en) | 2019-03-21 |
| CA3035712A1 (en) | 2018-03-15 |
| EP3510030A1 (en) | 2019-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190632A1 (es) | Compuestos 8-(azetidin-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y metodos de utilizacion de los mismos | |
| PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| PE20171307A1 (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| PE20090370A1 (es) | Derivados de heterociclo fusionado como inhibidores de quinasa | |
| PE20170189A1 (es) | Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1 | |
| PE20120534A1 (es) | PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt | |
| PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
| PE20070004A1 (es) | Imidazoquinolinas como inhibidores de quinasa de lipido | |
| PE20100741A1 (es) | COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38 | |
| PE20191499A1 (es) | Imidazopirrolopiridina como inhibidores de la familia de quinasas jak | |
| PE20210658A1 (es) | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat) | |
| EA202090659A1 (ru) | СОСТАВЫ, СОДЕРЖАЩИЕ 6-(2-ГИДРОКСИ-2-МЕТИЛПРОПОКСИ)-4-(6-(6-((6-МЕТОКСИПИРИДИН-3-ИЛ)МЕТИЛ)-3,6-ДИАЗАБИЦИКЛО[3.1.1]ГЕПТАН-3-ИЛ)ПИРИДИН-3-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИДИН-3-КАРБОНИТРИЛ | |
| AR077468A1 (es) | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa | |
| AR073551A1 (es) | Pirimidinas macrociclicas como inhibidores de proteina cinasa | |
| PE20050951A1 (es) | Compuestos mimeticos de glucocorticoides, metodos de preparacion y composiciones farmaceuticas | |
| PE20191236A1 (es) | Compuestos de pirazolopirimidina y metodos de uso de los mismos | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| PE20170663A1 (es) | Compuestos de 5- cloro- 2- difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos | |
| PE20091039A1 (es) | IMIDAZO PIRAZINAS FUSIONADAS ARILO Y HETEROARILO [1,5-a] COMO INHIBIDORES DE LA FOSFODIESTERASA 10 | |
| PE20120121A1 (es) | Derivados de imidazopirazina como inhibidores de syk | |
| PE20090492A1 (es) | Compuestos heterociclos como inhibidores de cinasa de fosfatidil-inositol-3 | |
| PE20120107A1 (es) | Inhibidores de proteina cinasa | |
| PE20180500A1 (es) | Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores del receptor muscarinico colinergico m1 | |
| PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA |